Patients who have adequate glycemic control and minimal hypoglycemic events with NPH insulin will likely not derive additional benefit from insulin glargine (in most studies, insulin glargine did not significantly reduce fasting blood glucose, fasting plasma glucose, or hemoglobin A1c compared to NPH insulin). They may, however, find once-daily dosing more convenient. Most trials showed a statistically significant decrease in the incidence of nocturnal and symptomatic hypoglycemia. This may not be as much of a concern in most patients with type 2 compared to type 1. The long-term safety and lower cost of NPH insulin compared with insulin glargine could limit its implementation.